RecoveryResearch Phase

Cathelicidin LL-37 Fragments

Topical, Subcutaneous injection

Overview

Cathelicidin LL-37 fragments are truncated sequences derived from the human antimicrobial peptide LL-37, which is a 37-amino acid cleavage product of the cathelicidin precursor hCAP18. These fragments retain antimicrobial, immunomodulatory, and wound healing properties while potentially offering improved stability or reduced cytotoxicity.

Mechanism of Action

Specific fragments have been designed to preserve angiogenic and chemotactic activities relevant to tissue repair..

Research Summary & Key Findings

In vitro studies have demonstrated that certain LL-37 fragments maintain broad-spectrum antimicrobial activity against bacteria and fungi. Preclinical wound models in rodents have shown acceleration of healing through enhanced re-epithelialization and modulation of inflammatory responses. Clinical development has been limited, with no approved therapeutic applications to date.

Clinical Status

Research Phase

Cathelicidin LL-37 Fragments is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

TopicalSubcutaneous injection

Related Peptides in Recovery

Find a Provider

Find a verified provider who offers Cathelicidin LL-37 Fragments therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Cathelicidin LL-37 Fragments.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.